von Willebrand factor propeptide to antigen ratio identifies platelet activation and reduced von Willebrand factor survival phenotype in mice

Essentials Reduced survival of von Willebrand factor (VWF) in plasma causes type 1C von Willebrand disease. Blood was collected from mouse strains by various methods and VWF propeptide and antigen assayed. VWF propeptide to antigen ratio identifies a reduced VWF survival phenotype in mice. This ratio validates the acceptability of murine blood samples for coagulation studies.

[1]  S. Haberichter.  von Willebrand factor propeptide: biology and clinical utility. , 2015, Blood.

[2]  J. Eikenboom,et al.  von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. , 2015, Blood.

[3]  E. Lerma,et al.  Thrombotic thrombocytopenic purpura. , 2014, Disease-a-month : DM.

[4]  R. Montgomery,et al.  Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis , 2012, Journal of thrombosis and haemostasis : JTH.

[5]  J. Gill,et al.  Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. , 2012, Blood.

[6]  D. Lillicrap,et al.  Pathologic mechanisms of type 1 VWD mutations R1205H and Y1584C through in vitro and in vivo mouse models. , 2011, Blood.

[7]  A. Tosetto,et al.  Reduced von Willebrand factor survival in von Willebrand disease: pathophysiologic and clinical relevance , 2009, Journal of thrombosis and haemostasis : JTH.

[8]  Robyn Roth,et al.  Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress. , 2009, Blood.

[9]  D. Tautz,et al.  Selection on cis-Regulatory Variation at B4galnt2 and Its Influence on von Willebrand Factor in House Mice , 2008, Molecular biology and evolution.

[10]  J. Goudemand,et al.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). , 2008, Blood.

[11]  P. Tucker,et al.  The endothelial-specific regulatory mutation, Mvwf1, is a common mouse founder allele , 2008, Mammalian Genome.

[12]  D. Motto,et al.  Thrombotic thrombocytopenic purpura in humans and mice. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  F. Rosendaal,et al.  von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis , 2006, Journal of thrombosis and haemostasis : JTH.

[14]  D. Bellissimo,et al.  Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. , 2006, Blood.

[15]  J. Long,et al.  Enhanced VWF biosynthesis and elevated plasma VWF due to a natural variant in the murine Vwf gene. , 2006, Blood.

[16]  P. Mannucci,et al.  Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor , 2006, Journal of thrombosis and haemostasis : JTH.

[17]  T. Pullen,et al.  P-selectin binds to the D'-D3 domains of von Willebrand factor in Weibel-Palade bodies. , 2006, Blood.

[18]  P. Lenting,et al.  Cysteine‐mutations in von Willebrand factor associated with increased clearance , 2005, Journal of thrombosis and haemostasis : JTH.

[19]  D. Ogden,et al.  Differential Kinetics of Cell Surface Loss of von Willebrand Factor and Its Propolypeptide after Secretion from Weibel-Palade Bodies in Living Human Endothelial Cells* , 2005, Journal of Biological Chemistry.

[20]  P. D. de Groot,et al.  An Experimental Model to Study the in Vivo Survival of von Willebrand Factor , 2004, Journal of Biological Chemistry.

[21]  J. Moake,et al.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. , 2004, Blood.

[22]  K. Mohlke,et al.  Mvwf, a Dominant Modifier of Murine von Willebrand Factor, Results from Altered Lineage-Specific Expression of a Glycosyltransferase , 1999, Cell.

[23]  P. V. van Genderen,et al.  Quantitative Analysis of von Willebrand Factor and Its Propeptide in Plasma in Acquired von Willebrand Syndrome , 1998, Thrombosis and Haemostasis.

[24]  W. Haefeli,et al.  Acute von Willebrand Factor Secretion from the Endothelium In Vivo: Assessment through Plasma Propeptide (vWf:AgII) Levels , 1997, Thrombosis and Haemostasis.

[25]  J. T. ten Cate,et al.  Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. , 1996, Blood.

[26]  K. Cooney,et al.  von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene. , 1995, Blood.

[27]  K. Cooney,et al.  von Willebrand disease in the RIIIS/J mouse is caused by a defect outside of the von Willebrand factor gene [published erratum appears in Blood 1995 Sep 15;86(6):2461] , 1994 .

[28]  J. Sweeney,et al.  The RIIIS/J inbred mouse strain as a model for von Willebrand disease. , 1990, Blood.

[29]  G. Mariani,et al.  Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. , 1985, Blood.

[30]  A. Girolami,et al.  Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. , 2002, Blood.

[31]  F. Liu,et al.  Hydrodynamics-based transfection: simple and efficient method for introducing and expressing transgenes in animals by intravenous injection of DNA. , 2002, Methods in enzymology.

[32]  C. Wollheim,et al.  Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. , 2000, The Journal of clinical investigation.

[33]  P. V. van Genderen,et al.  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY von Willebrand Factor Propeptide in Vascular Disorders: A Tool to Distinguish Between Acute and Chronic Endothelial Cell Perturbation , 1999 .